Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection

Transplantation

Volumn 61, Issue 9, 1996, Pages 1365-1369

  Millis, J Michael ^a,b   Woodle, E Steve ^a   Piper, James B ^a   Bruce, David S ^a   Newell, Kenneth A ^a   Seaman, David S ^a   Baker, Alfred L ^a   Hart, John ^a   Dasgupta, Kathy ^a   Thistlethwaite Jr , J Richard ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Section of Transplantation Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CROSS RESISTANCE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEROID THERAPY; SURVIVAL RATE;

ADULT; CYCLOSPORINE; DRUG RESISTANCE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER TRANSPLANTATION; METHYLPREDNISOLONE; MUROMONAB-CD3; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS;

EID: 9344243484     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605150-00014     Document Type: Article

References (18)

1. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344(8920): 423.
2. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331(17): 1110.
3. Woodle ES, Perdrizet GA, So SKS, White HM, Marsh JW. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. Clin Transpl 1995; 9: 45.
4. McDiarmid SV, Klintmalm GB, Busuttil RW. FK506 conversion for intractable rejection of the liver allograft. Transpl Int 1993; 6: 305.
5. Lewis WD, Jenkins RL, Burke PA, et al. FK506 rescue therapy in liver transplant recipients with drug resistant rejection. Transplant Proc 1991; 23: 2989.
6. Colonna JO, Millis JM, Martello J, et al. The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose. Transplant Proc 1989; 21 (1 Pt 2): 2247.
7. Mayes JT, Thistlethwaite JR, Stuart JK, Buckingham MR, Stuart FP. Reexposure to OKT3 in renal allograft recipients. Transplantation 1988; 45: 349.
8. Norman DJ, Shield CF, Henell KR, et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 1988; 46: 523.
9. First ME, Schroeder TJ, Burtubise PE, et al. Successful retreatment of allograft rejection with OKT3. Transplantation 1989; 47: 88.
10. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56(1): 88.
11. Hart J, Lewin KJ. Liver allograft pathology. Pathology: State of the Art Reviews 1994; 3(1): 207.
12. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283.
13. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK 506. Immunol Today 1992; 13: 136.
14. Shapiro M, Jordan M, Scantlebury V, et al. A prospective randomized trial of FK-506 in renal transplantation - a comparison between double and triple drug therapy. Clin Transplant 1994; 8: 508.
15. Jordan ML, Shapiro R, Vivas CA, et al. FK506 "rescue for resistant rejection of renal allografts under primary cyclosporine immunosuppression." Transplantation 1994; 57(6): 860.
16. Klintmalm GB, Gonwa T, Wiesner RH, et al. Use of FK 506 as rescue therapy for refractory rejection after liver transplantation. Transplant Proc 1993; 25: 679.
17. Klintmalm GB, Gonwa T, Wiesner RH, et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. Transplant Proc 1993; 25: 635.
18. Colonna JO, Goldstein LI, Brems JJ, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg 1987; 122(10): 1120.